Printer Friendly

Episurf Medical commences patient enrolment in US and Europe in IDE clinical trial.

NORDIC BUSINESS REPORT-June 24, 2020-Episurf Medical commences patient enrolment in US and Europe in IDE clinical trial


Episurf Medical AB (STO:EPISB), a provider of minimally invasive and individualised treatment alternatives for people with painful joint injuries, announced on Tuesday that the enrolment of patients has been initiated in the US and in Europe for the company's IDE clinical trial for the Episealer knee implant.

The clinical trial, EPIC-Knee Episealer Knee System IDE Clinical Study, is a prospective, randomised, controlled multi-centre study with two years' follow-up of 180 subjects. The clinical trial is conducted at several clinics in the US, Canada, Germany, UK and Denmark.

According to the company, this pivotal study is the single largest and most important clinical trial that it is engaged in, given that the US market is, by far, the largest orthopaedic market in the world. If the clinical results generated for the Episealer in Europe can be re-generated in the US, then the company expects a great future.

((Comments on this story may be sent to

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Article Type:Clinical report
Date:Jun 24, 2020
Previous Article:Alligator Bioscience announces receipt of first patent approval for drug candidate ATOR-1017.
Next Article:Saab to divest shares in Vricon to Maxar Technologies for USD117m.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters